Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.54 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.40 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.40 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.40 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391504 | 0.90 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3424934 | 0.87 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3392837 | 0.84 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL14567707 | 0.83 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL14506487 | 0.82 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL14506507 | 0.81 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL14506477 | 0.81 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539622 | 0.80 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539626 | 0.75 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3393890 | 0.75 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007035963-A2 | ANTI-TUMOR METHODS USING MULTI DRUG RESISTANCE INDEPENDENT SYNTHETIC HSP90 INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-7148228-B2 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 9/4885 |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.